Ketamine for OUD and Suicidal Ideation in the ED
NCT06111339 · Brigham and Women's Hospital
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Lower Suicidal Ideation
Measured over 7-day remote follow up; 14- day remote follow up; 28 days after being discharged from inpatient unit or emergency department.
Less Illicit Opioid Use
Measured over 28 days after being discharged from inpatient unit or emergency department.
Incidence of Serious Adverse Events (SAE)
Measured over From the beginning on the infusion, every 15 minutes throughout infusion, and at the end of the infusion.
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT06111339 on ClinicalTrials.gov →
Last updated in the registry 2025-04-08. Registry records change; this page reflects the data build of 2026-08-25.
Related